Literature DB >> 23562491

Inflammasome biology in fibrogenesis.

Xinshou Ouyang1, Ayaz Ghani, Wajahat Z Mehal.   

Abstract

Pathogens and sterile insults both result in an inflammatory response. A significant part of this response is mediated by cytosolic machinery termed as the inflammasome which results in the activation and secretion of the cytokines interleukin-1β (IL-1β) and IL-18. Both of these are known to result in the activation of an acute inflammatory response, resulting in the production of downstream inflammatory cytokines such as tumor necrosis factor (TNF-α), interferon-gamma (IFN-γ), chemotaxis of immune cells, and induction of tissue injury. Surprisingly this very acute inflammatory pathway is also vital for the development of a full fibrogenic response in a number of organs including the lung, liver, and skin. There is evidence for the inflammasome having a direct role on tissue specific matrix producing cells such as the liver stellate cell, and also indirectly through the activation of resident tissue macrophage populations. The inflammasome requires stimulation of two pathways for full activation, and initiating stimuli include Toll-like receptor (TLR) agonists, adenosine triphosphate (ATP), particulates, and oxidative stress. Such a role for an acute inflammatory pathway in fibrosis runs counter to the prevailing association of TGF-β driven anti-inflammatory and pro-fibrotic pathways. This identifies new therapeutic targets which have the potential to simultaneously decrease inflammation, tissue injury and fibrosis. This article is part of a Special Issue entitled: Fibrosis: Translation of basic research to human disease. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23562491     DOI: 10.1016/j.bbadis.2013.03.020

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  26 in total

Review 1.  Self-regulation and cross-regulation of pattern-recognition receptor signalling in health and disease.

Authors:  Xuetao Cao
Journal:  Nat Rev Immunol       Date:  2016-01       Impact factor: 53.106

2.  Glibenclamide protects against thioacetamide-induced hepatic damage in Wistar rat: investigation on NLRP3, MMP-2, and stellate cell activation.

Authors:  Durgesh Kumar Dwivedi; G B Jena
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-07-31       Impact factor: 3.000

3.  Asbestos-Induced Mesothelial to Fibroblastic Transition Is Modulated by the Inflammasome.

Authors:  Joyce K Thompson; Maximilian B MacPherson; Stacie L Beuschel; Arti Shukla
Journal:  Am J Pathol       Date:  2017-01-03       Impact factor: 4.307

4.  Effect of bevacizumab on the expression of fibrosis-related inflammatory mediators in ARPE-19 cells.

Authors:  San-Jun Chu; Zhao-Hua Zhang; Min Wang; Hai-Feng Xu
Journal:  Int J Ophthalmol       Date:  2017-03-18       Impact factor: 1.779

5.  Inhibition of acid-sensing ion channel 1a in hepatic stellate cells attenuates PDGF-induced activation of HSCs through MAPK pathway.

Authors:  Fan-Rong Wu; Chun-Xiao Pan; Chao Rong; Quan Xia; Feng-Lai Yuan; Jie Tang; Xiao-Yu Wang; Nan Wang; Wen-Lin Ni; Fei-Hu Chen
Journal:  Mol Cell Biochem       Date:  2014-06-18       Impact factor: 3.396

Review 6.  Inflammasome activation and function in liver disease.

Authors:  Gyongyi Szabo; Jan Petrasek
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-06-09       Impact factor: 46.802

7.  NLR Family Pyrin Domain-Containing 3 Inflammasome Activation in Hepatic Stellate Cells Induces Liver Fibrosis in Mice.

Authors:  Maria Eugenia Inzaugarat; Casey D Johnson; Theresa Maria Holtmann; Matthew D McGeough; Christian Trautwein; Bettina G Papouchado; Robert Schwabe; Hal M Hoffman; Alexander Wree; Ariel E Feldstein
Journal:  Hepatology       Date:  2019-01-03       Impact factor: 17.425

Review 8.  Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis.

Authors:  Wei Jia; Guoxiang Xie; Weiping Jia
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-10-11       Impact factor: 46.802

9.  NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.

Authors:  Auvro R Mridha; Alexander Wree; Avril A B Robertson; Matthew M Yeh; Casey D Johnson; Derrick M Van Rooyen; Fahrettin Haczeyni; Narci C-H Teoh; Christopher Savard; George N Ioannou; Seth L Masters; Kate Schroder; Matthew A Cooper; Ariel E Feldstein; Geoffrey C Farrell
Journal:  J Hepatol       Date:  2017-02-03       Impact factor: 25.083

10.  Increased Adipose Tissue Fibrogenesis, Not Impaired Expandability, Is Associated With Nonalcoholic Fatty Liver Disease.

Authors:  Joseph W Beals; Gordon I Smith; Mahalakshmi Shankaran; Anja Fuchs; George G Schweitzer; Jun Yoshino; Tyler Field; Marcy Matthews; Edna Nyangau; Darya Morozov; Bettina Mittendorfer; Marc K Hellerstein; Samuel Klein
Journal:  Hepatology       Date:  2021-06-22       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.